Carlyle Group Inc-The

Discover how Carlyle’s $750 M stake in Nxtra Data and sale to QIA reshape India’s data‑center and coatings markets—insights on growth, regulation, and portfolio strategy.

Resonetics’ acquisition of Resolution Medical expands its end‑to‑end medical‑device manufacturing, boosting NPI, clean‑room capacity, and regulatory expertise to drive higher margins and investor returns.

Explore Carlyle Group’s Rule 144 offering: 500k shares on Nasdaq, boosting liquidity, institutional access, and private‑equity transparency for savvy investors.

Lincoln Minerals’ 2025 half‑year report reveals deep losses, new exploration gains, and bold green‑hydrogen and graphite partnerships—yet highlights cash burn, regulatory risks, and a going‑concern warning.

UBS cuts Carlyle’s target price to $65 amid tighter regulation and weaker PE deal flow, highlighting risks and a cautious outlook for the private‑equity firm.

Explore how Carlyle’s diversified private‑equity, real‑asset, and ESG‑focused strategy offers institutional investors stable volatility, balanced valuation, and growth in digital infrastructure and emerging markets.

JPMorgan lifts Carlyle’s target, spotlighting its role in a high‑stakes Russian‑asset deal. Discover how regulatory risk, fee upside, and fierce competition shape Carlyle’s value‑creation prospects.

Explore how Carlyle Group’s 2026 strategy focuses on Corporate Private Equity, Real Assets, Global Credit and ESG‑driven Investment Solutions to drive growth, risk‑managed returns, and sustainable impact.

How Carlyle’s new analyst ratings and $22 billion deal reshape its risk‑reward profile in today’s tightening private‑equity market.

Analyze Carlyle Group’s high‑valuation, diversified portfolio and credit risk amid tightening markets to gauge future upside and investor confidence.